Effect of novobiocin on the viability of human gingival fibroblasts (HGF-1)

BMC Clinical Pharmacology

Andrzej Szkaradkiewicz²  Tomasz M Karpiński²  Anna K Szkaradkiewicz¹ 

[1] Department of Conservative Dentistry and Periodontology, University of Medical Sciences, Bukowska 70, str., 60-812, Poznań, Poland;Department of Medical Microbiology, University of Medical Sciences, Wieniawskiego 3, str., 61-712 Poznań, Poland

关键词: Cell death;    Viability;    Human gingival fibroblasts;    Hsp90;    Novobiocin;   

Others  :  860335
DOI  :  10.1186/2050-6511-15-25

 received in 2013-12-31, accepted in 2014-04-24,  发布年份 2014

【 摘 要 】

Background

Novobiocin is a coumarin antibiotic, which affects also eukaryotic cells inhibiting activity of Heat shock protein 90 (Hsp90). The Hsp90 represents a molecular chaperone critical for stabilization and activation of many proteins, particularly oncoproteins that drive cancer progression. Currently, Hsp90 inhibitors focus a significant attention since they form a potentially new class of drugs in therapy of cancer. However, in the process of tumorigenesis a significant role is played also by the microenvironment of the tumour, and, in particular, by cancer-associated fibroblasts (CAFs). This study aimed at examination of the effect played by novobiocin on viability of human gingival fibroblasts (HGF-1).

Methods

The studies were conducted using 24 h cultures of human gingival fibroblasts – HGF-1 (CRL-2014) in Chamber Slides, in presence of 0.1, 0.5, 1.0, 2.5 or 5.0 mM novobiocin. Cell viability was evaluated using fluorescence test, ATP assay and LDH release.

Results

Viability of HGF-1 was drastically reduced after 5 hour treatment with novobiocin in concentrations of 1 mM or higher. In turn, the percentage of LDH-releasing cells after 5 h did not differ from control value although it significantly increased after 10 h incubation with 1 mM and continued to increase till the 20th hour.

Conclusions

The obtained data indicate that novobiocin may induce death of human gingival fibroblasts. Therefore, application of the Hsp90 inhibitor in neoplastic therapy seems controversial: on one hand novobiocin reduces tumour-associated CAFs but, on the other, it may induce a significant destruction of periodontium.

【 授权许可】

   
2014 Szkaradkiewicz et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Limson BM, Romansky MJ: Novobiocin, a new antibiotic; laboratory and clinical evaluation of thirty patients with bacterial pneumonia. Antibiotic Med Clin Ther 1956, 2:277-281.
• [2]Gellert M, O’Dea MH, Itoh T, Tomizawa J: Novobiocin and coumermycin inhibit DNA supercoiling catalysed by DNA gyrase. Proc Natl Acad Sci U S A 1976, 73:4474-4478.
• [3]Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR: Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 1978, 75:4838-4842.
• [4]Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers L: The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000, 275(47):37181-37186.
• [5]Donnelly A, Blagg BSJ: Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008, 15(26):2702-2717.
• [6]Piper PW, Millson SH: Spotlight on the microbes that produce heat shock protein 90-targeting antibiotics. Open Biol 2012, 2(12):120138.
• [7]Lorusso G, Ruegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008, 130:1091-1103.
• [8]Rӓsӓnen K, Vaheri A: Activation of fibroblasts in cancer stroma. Exp Cell Res 2010, 316:2713-2722.
• [9]Cirri P, Chiarugi P: Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012, 31:195-208.
• [10]Polanska UM, Orimo A: Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013, 228:1651-1657.
• [11]Wright WE: Periodontium destruction associated with oncology therapy. Five case reports. J Periodontol 1987, 58(8):559-563.
• [12]Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Popplewell L, Maghami E: Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012, 62(6):400-422.
• [13]Bresnick EH, Dalman FC, Sanchez ER, Pratt WB: Evidence that the 90-kDa heat shock protein is necessary for the steroid binding conformation of the L cell glucocorticoid receptor. J Biol Chem 1989, 264(9):4992-4997.
• [14]Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK – and AKT – related pathways. Blood 2003, 102:1284-1832.
• [15]Blagosklonny MV, Toretsky J, Bohen S, Neckers L: Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 1996, 93(16):8379-8383.
• [16]Kone BC: Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand 2000, 168(1):27-31.
• [17]Gao Z, Garcia-Echeverri C, Jensen MR: Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 2010, 13(2):193-202.
• [18]Geller R, Vignuzzi M, Andino R, Frydman J: Evolutionary constraints onchaperone – mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 2007, 21:195-205.
• [19]Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217.
• [20]Shahinas D, Liang M, Datti A, Pillai DR: A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 2010, 53:3552-3557.
• [21]Koka S, Reinhardt RA: Periodontal pathogen-related stimulation indicates unique phenotype of primary cultured human fibroblasts from gingiva and periodontal ligament: implications for oral health disease. J Prosthet Dent 1997, 77:191-196.
• [22]Ara T, Kurata K, Hirai K, Uchihashi T, Uematsu T, Imamura Y, Furusawa K, Kurihara S, Wang PL: Human gingival fibroblasts are critical in sustaining inflammation in periodontal disease. J Periodontal Res 2009, 44:21-27.
• [23]Weyermann J, Lochmann D, Zimmer A: A practical note on the use of cytotoxicity assays. Int J Pharm 2005, 288:369-376.
• [24]Calamia V, De Andrés MG, Oreiro N, Ruiz-Romero C, Blanco FJ: Hsp90 inhibition modulates nitric oxide production and nitric oxide-induced apoptosis in human chondrocytes. BMC Musculoskelet Disord 2011, 12:237. BioMed Central Full Text
• [25]Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BSJ, Robertson JD: KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 2009, 76(6):1314-1322.
• [26]Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX, Chen YZ: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008, 22:1402-1409.
• [27]Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
• [28]Le Bras G, Radanyi C, Peyrat JF, Brion JD, Alami M, Marsaud V, Stella B, Renoir JM: New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem 2007, 50(24):6189-6200.
• [29]Schwab BL, Guerini D, Didszun C, Bano D, Ferrando-May E, Fava E, Tam J, Xu D, Xanthoudakis S, Nicholson DW, Carafoli E, Nicotera P: Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ 2002, 9:818-831.
• [30]Skulachev VP: Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006, 11:473-485.